Part 2/8:
As the CEO reflects on bringing Fortress Biotech into the public eye, he acknowledges the precariousness that comes with it. The firm's achievements make it a target; the arrival of a determined corporate raider—dubbed "the only corporate raider in the world with three first names"—sets off alarm bells. The raider's bear hug letter exudes coyness, masking a sinister intent to seize control of Fortress's promising drug pipeline for a fraction of its worth.
Despite the looming threat, the CEO stands resolute—Fortress Biotech is “not for sale.” The stakes are high; the company's future hinges not only on its market value but also on the integrity of its groundbreaking research.